Defence ceremony and presentation of doctoral degree, Emilia Sawicki, Utrecht University, the Netherlands 29 March 2017, 2:30 PM Utrecht, The Netherlands, March 27, 2017 / B3C newswire / – Coming Wednesday (29 March 2017), Dutch pharmacist Emilia Sawicki …
A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countries The open-label extension study (the MAP US2 study) is …
MammaPrint® is the first and only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT trial Irvine, CA, USA and Amsterdam, the Netherlands, March 21, 2017 / B3C newswire / -- Agendia, a world leader in …
Kraków, Poland, March 17, 2017 / B3C newswire / -- Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced today that the first patient was dosed with SEL24 in a …
15 featured abstracts at the 15th St Gallen International Breast Cancer Conference underscore the growing adoption of the company’s cutting-edge genomic test to identify those patients who will benefit from chemotherapy after breast cancer surgery New real …
Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives FDA approval as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor Novartis drug Kisqali® (ribociclib, LEE011) receives marketing …
Kraków, Poland, March 13, 2017 / B3C newswire / -- Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the …
2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer Irvine, CA, USA and Amsterdam, the …
Vienna, Austria, March 06, 2017 / B3C newswire / -- Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces the appointment of Igor Matushansky, M.D., Ph.D. as Global Head, Research and …
First four drug discovery programmes now launched in collaboration with academics at all three partner universities - spanning a variety of disease areas and drug modalities Recruited highly experienced Project Directors with track records of delivering …
Hamburg, Germany, February 21, 2017 / B3C newswire / -- AmpTec GmbH is an ISO 13485:2009 certified Provider of High Quality synthetic nucleic acids for worldwide leading companies in the fields of molecular diagnostics, biotechnology and therapeutic …
Freiburg, Germany, February 21, 2017 / B3C newswire / -- CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, started facility expansions as more customers approach late-stage …
Sartorius and EMBL join forces to offer advanced training and science education Sartorius is now a member of the group of corporate EMBL partners aiming to connect industry to academia Goettingen, Germany, February 17, 2017 / B3C newswire / -- Sartorius, a …
NEUROCAP® 3-month interim data show an average pain reduction of 84% Final patient recruited in “STOP NEUROMA” clinical study, full data due to be reported by Q3 2018. Groningen, The Netherlands, February 16, 2017 / B3C newswire / -- Polyganics, a …
First comparison of a biomarker analysis by RT-qPCR (MammaTyper®) versus visual or computer-assisted immunohistochemistry (IHC) in subtyping mammary carcinomas Significantly more precise prediction of pathologically complete remission in a neoadjuvant …
Top-line results are expected in the second quarter of 2017 The randomized, double-blind, placebo-controlled Phase III study is evaluating the safety and efficacy of BEKINDA® 24mg in patients with acute gastroenteritis and gastritis (the GUARD study) Acute …
hypACT™ serum therapy for the regeneration of osteoarthritic bone and cartilage is entering clinical development Krems an der Donau, Austria, February 09, 2017 / B3C newswire / --OrthoSera GmbH, an orthobiologics company developing serum-based solutions …
Leuven, Belgium, February 08, 2017 / B3C newswire / -- Trod Medical NV, the medical device company with FDA-cleared and CE Marked products for focal ablation, announces the issuance of a new patent allowance by the United States Patent and Trademark Office …
Sunnyvale, California and Leiden, the Netherlands, February 06, 2017 / B3C newswire / -- In a move to serve customers with ready-to-use solutions for organ-on-a-chip model development and analysis, MIMETAS and Molecular Devices will combine marketing …
Laupheim and Munich/Martinsried, Germany, February 02, 2017 / B3C newswire / -- Rentschler Biotechnologie GmbH, Laupheim and Leukocare AG, Martinsried today announced a strategic alliance under which Leukocare will become the specialized technology partner …
